Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:RARENASDAQ:XFORNASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$64.99+0.1%$64.77$47.88▼$107.37$3.58B0.33552,811 shs119,224 shsRAREUltragenyx Pharmaceutical$38.90-0.2%$37.54$29.59▼$60.37$3.65B0.61815,780 shs236,026 shsXFORX4 Pharmaceuticals$3.85-10.7%$8.06$3.74▼$36.00$666.86M0.5891,718 shs178,687 shsZLABZai Lab$31.36-1.0%$33.29$15.73▼$39.77$3.45B1.09857,216 shs228,648 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+0.37%+2.07%-0.99%-3.82%+29.85%RAREUltragenyx Pharmaceutical+2.39%+4.22%+7.65%-10.18%-8.37%XFORX4 Pharmaceuticals-0.92%-28.63%-39.23%-78.30%-87.17%ZLABZai Lab-0.47%-5.74%-12.31%+13.83%+100.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.8296 of 5 stars3.60.00.00.03.02.50.0RAREUltragenyx Pharmaceutical4.3486 of 5 stars4.51.00.03.82.92.50.6XFORX4 Pharmaceuticals3.8447 of 5 stars3.52.00.04.61.61.70.6ZLABZai Lab2.1548 of 5 stars3.41.00.00.02.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.14Buy$110.6770.28% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$92.79138.50% UpsideXFORX4 Pharmaceuticals 3.00Buy$85.002,107.79% UpsideZLABZai Lab 2.75Moderate Buy$47.3751.04% UpsideCurrent Analyst Ratings BreakdownLatest XFOR, ZLAB, RARE, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.003/27/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.00 ➝ $45.003/27/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025XFORX4 PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.003/17/2025RAREUltragenyx PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.003/13/2025ZLABZai LabJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $51.003/7/2025ZLABZai LabScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/4/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025ZLABZai LabBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$29.00 ➝ $36.102/26/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$118.00 ➝ $118.002/18/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$121.00 ➝ $136.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M33.16N/AN/A$9.97 per share6.52RAREUltragenyx Pharmaceutical$560.23M6.52N/AN/A$2.76 per share14.10XFORX4 Pharmaceuticals$2.56M261.48N/AN/A$0.31 per share12.42ZLABZai Lab$398.99M8.66N/AN/A$8.05 per share3.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)RAREUltragenyx Pharmaceutical-$569.18M-$6.34N/AN/AN/A-101.60%-193.80%-38.15%5/6/2025 (Estimated)XFORX4 Pharmaceuticals-$101.17M-$0.19N/AN/AN/AN/A-236.19%-75.14%5/1/2025 (Estimated)ZLABZai Lab-$334.62M-$2.59N/AN/AN/A-76.14%-36.97%-27.10%5/8/2025 (Estimated)Latest XFOR, ZLAB, RARE, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ACLXArcellx-$0.84N/AN/AN/A$19.51 millionN/A5/8/2025Q1 2025ZLABZai Lab-$0.33N/AN/AN/A$118.40 millionN/A5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.58N/AN/AN/A$145.98 millionN/A5/1/2025Q1 2025XFORX4 Pharmaceuticals-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million3/25/2025Q4 2024XFORX4 Pharmaceuticals-$5.10-$6.00-$0.90-$0.20$1.07 million$1.43 million2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/27/2025Q4 2024ZLABZai Lab-$0.61-$0.80-$0.19-$0.80$110.15 million$109.07 million2/13/2025Q4 2024RAREUltragenyx Pharmaceutical-$1.32-$1.39-$0.07-$1.39$163.23 million$164.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29RAREUltragenyx PharmaceuticalN/A2.372.65XFORX4 Pharmaceuticals1.264.894.80ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%RAREUltragenyx Pharmaceutical97.67%XFORX4 Pharmaceuticals72.03%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipACLXArcellx6.24%RAREUltragenyx Pharmaceutical5.50%XFORX4 Pharmaceuticals1.62%ZLABZai Lab13.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.07 million50.70 millionOptionableRAREUltragenyx Pharmaceutical1,31093.89 million86.99 millionOptionableXFORX4 Pharmaceuticals80173.66 million167.78 millionOptionableZLABZai Lab1,950110.13 million94.24 millionOptionableXFOR, ZLAB, RARE, and ACLX HeadlinesRecent News About These CompaniesZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's What HappenedMay 1 at 12:19 PM | marketbeat.comPrice T Rowe Associates Inc. MD Raises Position in Zai Lab Limited (NASDAQ:ZLAB)May 1 at 5:10 AM | marketbeat.comLegal & General Group Plc Reduces Holdings in Zai Lab Limited (NASDAQ:ZLAB)April 27, 2025 | marketbeat.comZai Lab presents data from studies evaluating two oncology therapiesApril 26, 2025 | markets.businessinsider.comXTX Topco Ltd Has $353,000 Position in Zai Lab Limited (NASDAQ:ZLAB)April 26, 2025 | marketbeat.comZai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025April 25, 2025 | businesswire.comMarshall Wace LLP Acquires Shares of 288,992 Zai Lab Limited (NASDAQ:ZLAB)April 25, 2025 | marketbeat.comTownsquare Capital LLC Invests $243,000 in Zai Lab Limited (NASDAQ:ZLAB)April 25, 2025 | marketbeat.comCantor Fitzgerald Reduces Earnings Estimates for Zai LabApril 25, 2025 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?April 24, 2025 | marketbeat.comEversept Partners LP Has $2.70 Million Stock Position in Zai Lab Limited (NASDAQ:ZLAB)April 24, 2025 | marketbeat.comZai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual MeetingApril 23, 2025 | finance.yahoo.comRock Springs Capital Management LP Decreases Stock Position in Zai Lab Limited (NASDAQ:ZLAB)April 23, 2025 | marketbeat.comB Group Inc. Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB)April 23, 2025 | marketbeat.comCapital International Investors Purchases 120,000 Shares of Zai Lab Limited (NASDAQ:ZLAB)April 23, 2025 | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Position Boosted by Renaissance Technologies LLCApril 22, 2025 | marketbeat.comZai Lab announces China NMPA acceptance of repotrectinib sNDAApril 21, 2025 | markets.businessinsider.comZai Lab Flat as China Okays ApplicationApril 21, 2025 | baystreet.caScotiabank Keeps Their Buy Rating on Zai Lab (ZLAB)April 21, 2025 | markets.businessinsider.comZai Lab gets China's acceptance for label expansion of repotrectinibApril 21, 2025 | msn.comZai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid TumorsApril 21, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatD-Wave Quantum Slides on Chip News: Opportunity to Buy?By Nathan Reiff | April 21, 2025View D-Wave Quantum Slides on Chip News: Opportunity to Buy?XFOR, ZLAB, RARE, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$64.99 +0.04 (+0.06%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Ultragenyx Pharmaceutical NASDAQ:RARE$38.90 -0.08 (-0.19%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.X4 Pharmaceuticals NASDAQ:XFOR$3.85 -0.46 (-10.67%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.Zai Lab NASDAQ:ZLAB$31.36 -0.33 (-1.04%) As of 01:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
